Research
Hormonal
Existing pharmaceuticals and bariatric surgeries have limited efficacy and side effects.
Awareness of the limitations of current treatments can guide practitioners in exploring new options.
StrongSupportsmedium confidence
Despite the existing pharmaceuticals and bariatric surgeries, these approaches manifest limited efficacy or accompany various side effects.
Why this rating
The abstract provides a critical overview of existing treatments.
Source
Current Role and Potential of Polymeric Biomaterials in Clinical Obesity Treatment
Rui‐Chian Tang et al. · Biomacromolecules · 2023
DOI 10.1021/acs.biomac.3c00388
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →